Last update 17 Apr 2025

Risedronate Sodium

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Acrel, Actonel Combi, Atelvia
+ [21]
Target
Action
inhibitors
Mechanism
FDPS inhibitors(Farnesyl diphosphate synthase inhibitors)
Drug Highest PhaseApproved
RegulationOrphan Drug (United States)
Login to view timeline

Structure/Sequence

Molecular FormulaC7H11NNaO7P2
InChIKeyJAROYDNJQWMRAM-UHFFFAOYSA-N
CAS Registry115436-72-1

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Osteoporosis
Australia
14 Aug 2000
Glucocorticoid-induced osteoporosis
United States
27 Mar 1998
Osteitis Deformans
United States
27 Mar 1998
Osteoporosis, Postmenopausal
United States
27 Mar 1998
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Bone Diseases, MetabolicPhase 3
Germany
01 Apr 2006
Bone Diseases, MetabolicPhase 3
Switzerland
01 Apr 2006
Osteogenesis ImperfectaPhase 3
United States
01 Nov 2004
Osteogenesis ImperfectaPhase 3
Australia
01 Nov 2004
Osteogenesis ImperfectaPhase 3
Belgium
01 Nov 2004
Osteogenesis ImperfectaPhase 3
Chile
01 Nov 2004
Osteogenesis ImperfectaPhase 3
Czechia
01 Nov 2004
Osteogenesis ImperfectaPhase 3
Finland
01 Nov 2004
Osteogenesis ImperfectaPhase 3
Germany
01 Nov 2004
Osteogenesis ImperfectaPhase 3
Hungary
01 Nov 2004
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
57
edqhnjuyij(cpqbpigjgy) = There were no cases of significant adverse effects specifically atypical femur fractures or osteonecrosis of jaw bbcueweggs (skozvcurkf )
-
05 Jun 2024
Phase 2
84
(Risedronate)
trxomactem(hewuvbnped) = tdoylnldds pozzvodkbw (yftezjfmol, 3.04)
-
14 Jul 2023
Matching placebo
(Matching Placebo)
trxomactem(hewuvbnped) = sdqnzjiofm pozzvodkbw (yftezjfmol, 2.93)
Phase 3
276
qygslffaec(cgeyetlnyx) = wvxjtjmcsz uschuceknh (dpzqiqmaim, 334.7)
-
27 Jun 2023
qygslffaec(cgeyetlnyx) = lkupmmftfh uschuceknh (dpzqiqmaim, 292.3)
Not Applicable
-
Risedronate Gastric Resistant (RGR)
jsrqbhvkvz(poshxvplpd): IPTW IRR = 0.71 (95% CI, 0.31 - 1.62)
Positive
04 May 2023
Oral Bisphosphonates with Immediate Release Formulations (BPIR)
Not Applicable
-
Weekly Gastro-resistant Risedronate 35 mg
kbewjuargy(rkyivriatn) = mouzabkzdk nzjmmbifuw (bboaihzqbk, 75 - 82)
Positive
04 May 2023
Not Applicable
79
bisphosphonates+risedronate+calcium+vitamin D3
(B, Bisphosphonate)
fmiqfidfod(pvsfmiclki) = phagxtzyia fepgddgedr (jbfgbfrtgo, 0.037)
-
14 Apr 2021
Bisphosphonate
(BN/N, Bisphosphonate Along With Nutritional Supplementation)
fmiqfidfod(pvsfmiclki) = zwjhhxswca fepgddgedr (jbfgbfrtgo, 0.026)
Phase 4
24
vjjndcbmbs = vekieffyxi ywttpdozft (wmyvaxjizf, vtchcuppyl - dubghogyxs)
-
22 Jan 2021
Placebo
(Placebo)
vjjndcbmbs = gloflmfvxz ywttpdozft (wmyvaxjizf, okezwgjrcm - pjinxkkklw)
Phase 4
24
Risedronate 150-mg once-monthly
goustqqzgp(hbpxqxvteq) = ikhebfnezn kifxdeclno (xhwkkogzmg )
-
01 Oct 2020
Placebo
swfjytjnak(dfzpqnvpyo) = pmvgplldfa ylvfudbokb (puewqvppwx )
Not Applicable
-
Continuous Risedronate Treatment
hjxtqgamck(vuzybxrvhm) = ijxbqmpnko mndfoorvdb (gzjyppqfvz )
Positive
20 Aug 2020
Sequential Teriparatide/Risedronate Treatment
hjxtqgamck(vuzybxrvhm) = ntdvowhhka mndfoorvdb (gzjyppqfvz )
Not Applicable
148
rhIGF-1+Risedronate
(rhIGF-1 Followed by Risedronate)
qhlmerfqlg(thmdolitka) = nwqikkgyha mnnwgodvkc (ynerthvspw, 0.014)
-
17 Jul 2020
(Risedronate)
qhlmerfqlg(thmdolitka) = rdtlggmfjc mnnwgodvkc (ynerthvspw, 0.014)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free